The company's lead asset, NSI-189, is a new chemical entity in clinical development for major depressive disorder (MDD) and in preclinical development for Angelman syndrome, irradiation-induced cognitive impairment, neuropathy associated with type 1 and type 2 diabetes, and stroke.

Neuralstelm's lead stem cell therapy candidate, NSI-566, is a spinal cord-derived neural stem cell line being tested in amyotrophic lateral sclerosis (ALS), chronic spinal cord injury (cSCI), and ischemic stroke.

The company has a proprietary neural stem cell technology, which uses regionally specific neural stem cells for the development of CNS therapies.